Vaccine Adjuvants Market Size, Share, Growth Analysis, By Type(Pathogen-Based Adjuvants and Particulate Adjuvants), By Route of Administration(Intramuscular Route, and Intradermal Route), By Region - Industry Forecast 2024-2031

Global Vaccine Adjuvants Market size was valued at USD 893.23 million in 2022 and is poised to grow from USD 1018.19 million in 2023 to USD 2902.45 million by 2031, growing at a CAGR of 13.99% in the forecast period (2024-2031).

The growing prevalence of life-threatening diseases such as cervical cancer, Human Papillomavirus (HPV), HIV, and tuberculosis, has led to an increased demand for adjuvants. These adjuvants play a crucial role in enhancing the efficacy of vaccines against these infectious diseases. Furthermore, there is a rising focus on developing vaccines with long-lasting immunization effects to combat existing and emerging diseases. This emphasis on sustained protection has further fueled the demand for adjuvants in the market. Adjuvant research has become increasingly important in the development of vaccines, as innovative vaccine antigens often exhibit inadequate immunogenicity on their own. The market growth is also attributed to the increasing utilization of recombinant and synthetic vaccines. These advanced vaccines rely on adjuvants to enhance their effectiveness, thereby driving the expansion of the market in the upcoming years. Major players in the industry are actively involved in the discovery and development of new adjuvants to combat fatal diseases. Notably, there are promising products like AS01, ISCOM & ISCOMMATRIX, and AS02 that are currently undergoing clinical trials. The introduction of these pipeline drugs is expected to further propel the market growth. In the United States, a developed country with a significant population and a high influx of travelers, the demand for immunization is substantial. This demand is primarily driven by the need to ensure the safety and well-being of the local population. Moreover, favorable government initiatives aimed at immunizing people against serious diseases are anticipated to contribute to market growth. An example of such an initiative is the program initiated by the National Institute of Allergy and Infectious Diseases, which focuses on advancing the development and utilization of adjuvants for human use.